CLAIMS:

1. The use of an antibody which binds to LY75 in the manufacture of a medicament for the treatment or prophylaxis of a cancer selected from the group consisting of lymphoma, myeloma, leukaemia, bladder cancer, breast cancer, gastric cancer, esophagus cancer and head and neck cancer wherein LY75 is expressed in said cancer and wherein said antibody is conjugated to a cytotoxic moiety or a radioactive isotope.

2. The use according to claim 1, wherein the lymphoma is selected from the group consisting of non-Hodgkin's lymphoma, Diffuse Large B-Cell Lymphoma, B-Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT), T-Cell/Histiocyte-Rich B-Cell Lymphoma, Burkitt Lymphoma, Lymphoplasmacytic Lymphoma, Small Lymphocytic Lymphoma, Marginal Zone Lymphoma, T-Cell Lymphoma, Peripheral T-Cell Lymphoma, Anaplastic Large Cell Lymphoma and AngioImmunoblastic T-Cell Lymphoma.

3. The use according to claim 1 or claim 2, wherein the antibody binds specifically to LY75.

4. The use according to any one of claims 1 to 3, wherein the antibody is a monoclonal antibody, a chimeric antibody, a human antibody, a humanized antibody, a single chain antibody, a defucosylated antibody or a bispecific antibody, or antigen-binding portion thereof.

5. The use according to claim 4, wherein the antibody is a domain antibody.

6. The use according to claim 1 wherein the cytotoxic moiety is selected from the group consisting of duocarmycins, calicheamicins, maytansines and auristatins, or derivatives thereof.

7. The use according to any preceding claim, wherein the antibody is an antibody drug conjugate.

8. The use according to claim 1, wherein the cancer is multiple myeloma or Triple-Negative breast cancer.

CLAIMS:

1. The use of a monoclonal antibody which specifically binds to LY75 in the manufacture of a medicament for the treatment of a cancer selected from the group consisting of lymphoma, myeloma, leukaemia, bladder cancer, breast cancer, gastric cancer, esophagus cancer and head and neck cancer wherein LY75 is expressed in said cancer and wherein said monoclonal antibody is conjugated to a cytotoxic moiety, wherein said monoclonal antibody is a chimeric antibody, a human antibody, a humanized antibody, or an antigen-binding portion thereof.

2. The use according to claim 1, wherein the lymphoma is selected from the group consisting of non-Hodgkin's lymphoma, Diffuse Large B-Cell Lymphoma, B-Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT), T-Cell/Histiocyte-Rich B-Cell Lymphoma, Burkitt Lymphoma, Lymphoplasmacytic Lymphoma, Small Lymphocytic Lymphoma, Marginal Zone Lymphoma, T-Cell Lymphoma, Peripheral T-Cell Lymphoma, Anaplastic Large Cell Lymphoma and AngioImmunoblastic T-Cell Lymphoma.

3. The use according to claim 1 wherein the cytotoxic moiety is selected from the group consisting of duocarmycins, calicheamicins, maytansines and auristatins,.

4. The use according to any preceding claim, wherein the antibody is an antibody drug conjugate.

5. The use according to claim 1, wherein the cancer is multiple myeloma or Triple-Negative breast cancer.